Regulatory Lilly plans Q1 2027 filing for obesity triple retatrutide PharmaphorumArmed with new pivotal trial results, Eli Lilly is preparing to file for approval of its triple-acting weight-loss therapy, retatrutide, next year.Metabolic & GLP-1Read full story pharminent July 23, 2026 (Last updated: July 23, 2026) Pharmaphorum Armed with new pivotal trial results, Eli Lilly is preparing to file for approval of its triple-acting weight-loss therapy, retatrutide, next year. Metabolic & GLP-1 Read full story Post navigation Previous: GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drugNext: Lilly’s Retatrutide Hits 22.6% Weight Loss in Phase 3, But Cardiovascular Benefit Remains Elusive Related Stories Regulatory FDA clears Takeda, Protagonist’s first-in-class PV drug pharminent August 31, 2026 Regulatory FDA green lights Priovant drug for rare skin disease pharminent August 28, 2026 Regulatory Neurocrine receives FDA IND Acceptance for Alzheimer’s Ph2 pharminent August 26, 2026